^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STK11 mutation

    i
    Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
    Entrez ID:
    6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    19h
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses. (PubMed, Clin Cancer Res)
    KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in co-mutational landscape and survival differences. Immunotherapy-based regimens were associated with more favorable outcomes compared to chemotherapy, particularly in patients with high PD-L1 expression, underscoring the importance of subtype-specific molecular characterization in clinical decision-making.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • PD-L1 overexpression • STK11 mutation • KEAP1 mutation • KRAS Q61
    9d
    In silico analysis of driver genes in squamous cell carcinoma of the cervix: insights into their biological functions, prognosis, immune infiltration, and therapy. (PubMed, World J Surg Oncol)
    Collectively, our analysis describes the driver genes and mutation characteristics in SCC. The multi-cohort and network-based framework employed in this study identifies candidate hub genes that warrant further clinical investigation in cervical cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • FAT1 (FAT atypical cadherin 1) • EP300 (E1A binding protein p300) • CASP8 (Caspase 8)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • ARID1A mutation • STK11 mutation
    |
    Herceptin (trastuzumab) • everolimus • Piqray (alpelisib)
    9d
    IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=54, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: May 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • PD-1 (Programmed cell death 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    PIK3CA mutation • PTEN mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation
    |
    Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090
    14d
    A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening (clinicaltrials.gov)
    P=N/A, N=79, Recruiting, Memorial Sloan Kettering Cancer Center
    New trial
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • APC (APC Regulator Of WNT Signaling Pathway) • EPCAM (Epithelial cell adhesion molecule) • PRSS1 (Serine Protease 1) • CTRC (Chymotrypsin C)
    |
    TP53 mutation • BRCA1 mutation • ATM mutation • STK11 mutation • PALB2 mutation
    16d
    STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer. (PubMed, Curr Oncol)
    Beyond immunotherapy, STK11 mutations confer poor outcomes across targeted therapies, including KRAS G12C inhibitors, with KEAP1 co-mutation serving as a strong negative predictor of efficacy. In this review we present an overview of STK11 function and its role in tumor biology, highlight the prognostic and predictive potential of STK11 mutations in the context of NSCLC treatment and summarize the emerging treatment strategies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • KRAS mutation • STK11 mutation • KEAP1 mutation
    17d
    Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS G12C NSCLC. (PubMed, Sci Rep)
    In plasma, twelve genes were consistently detected, and SHOC2, YAP1, LZTR1, RGS3, and ZDHHC7 were significantly upregulated at week 6. Low tumor LIFR expression was associated with poorer survival, supporting its potential as a prognostic biomarker and highlighting the feasibility of plasma-based gene expression monitoring.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • YAP1 (Yes associated protein 1) • LIFR (LIF Receptor Subunit Alpha) • ENO1 (Enolase 1) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • STK11 mutation • KRAS wild-type • KEAP1 mutation • RAS wild-type • KRAS G12
    18d
    Adrenocortical Carcinoma in Peutz-Jeghers Syndrome With a Rare STK11 Pathogenic Germline Variant: A Case Report. (PubMed, Cancer Rep (Hoboken))
    This is the second report of ACC associated PJS in a rare germline variant of STK11. Although rare, loss of STK11 function may lead to cancers outside expected sites in PJS cases.
    Journal
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    OncoGuide™ NCC Oncopanel System
    |
    cisplatin • doxorubicin hydrochloride • etoposide IV • Lysodren (mitotane)
    20d
    The potential clinical benefit of routine comprehensive genomic profiling in non-small cell lung cancer for the detection of prognostic co-mutations - A multicenter next generation sequencing study. (PubMed, Cancer Treat Res Commun)
    This study demonstrated the broad spectrum of variants in STK11, KEAP1 and TP53 in routine panel-based DNA NGS, with 70.3% of the samples without AGA showing a potential clinically relevant mutation in TP53, STK11 and/or KEAP1.
    Journal • Next-generation sequencing • IO biomarker
    |
    TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • STK11 mutation • KEAP1 mutation
    20d
    Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies. (PubMed, J Clin Oncol)
    Cellular immunotherapies (tumor-infiltrating lymphocytes, T-cell receptors, chimeric antigen receptor-T), antibody-drug conjugates, and vaccines offer complementary means to restore antitumor immunity. Advancing the field will require biomarker-driven patient selection and rational combinations to overcome AR and achieve more durable, personalized immunotherapy outcomes in NSCLC.
    Preclinical • Review • Journal • IO biomarker
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • AXL (AXL Receptor Tyrosine Kinase) • LAG3 (Lymphocyte Activating 3) • B2M (Beta-2-microglobulin) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    STK11 mutation • KEAP1 mutation
    24d
    Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC). (PubMed, Br J Cancer)
    Durable responses to ICI in mCC, although uncommon, are associated with prolonged disease control and may persist after treatment discontinuation. Specific clinical and molecular features are strongly associated with long-term benefit and may help refine patient selection for immunotherapy.
    Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
    |
    PIK3CA mutation • STK11 mutation
    25d
    Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation-Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study. (PubMed, World J Oncol)
    In this real-world cohort of actionable mutation-negative NSCLC cases, we did not detect significant prognostic associations for TP53, STK11, and KEAP1 mutations, and their incidence was similar between de novo and recurrent disease. These findings underscore the need for larger studies to evaluate the prognostic utility of these mutations in this clinical context.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • STK11 mutation • KEAP1 mutation
    25d
    Acute intestinal intussusception revealing Peutz-Jeghers Syndrome in a 16-year-old male: a case report. (PubMed, Int J Surg Case Rep)
    Prompt diagnosis, surgical management, and comprehensive evaluation for additional polyps are essential to prevent recurrence and complications. Long-term multidisciplinary follow-up is vital due to the high risk of malignancy and recurrence inherent to PJS.
    Journal
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation